‘Groundbreaking' drug could slow down progression of type 1 diabetes
With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body.
If blood sugar is too high or low, it can cause serious health problems and even death.
People with type 1 therefore need daily insulin.
Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition.
She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1.
A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS.
The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin.
'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition.
'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.'
The new drug teplizumab must be given at the earliest stage of the disease to be effective.
Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes.
'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin.
'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment.
'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.'
Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes.
The hope is more people could be offered the drug to delay type 1.
Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free.
'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit.
'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale.
'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.'
Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose.
'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Belfast Telegraph
22 minutes ago
- Belfast Telegraph
‘Groundbreaking' drug could slow progression of type 1 diabetes
Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body.
BBC News
an hour ago
- BBC News
Lampard: Poor Essex mental health care cited in NHS 10-year plan
Mental health services where more than 2,000 in-patients died between 2000 and the end of 2023 have been cited in the government's 10-Year Health Plan as an example of poor practice, a lawyer told a Lampard Inquiry into the care of patients saw counsel Nicolas Griffin reference the government's comments, acknowledging systemic and avoidable harm in mental health services, including in health plan cites issues like toxic culture, incompetent leadership, rampant blame and a lack of fourth public Lampard hearing will focus on evidence from bereaved families over the next two weeks. The majority of mental health services in Essex are now run by Essex Partnership University NHS Foundation Trust (EPUT). Independent lawyer for the inquiry, Mr Griffin, told the hearing that personal testimonies would guide its investigations into any systemic failings."The Inquiry is aware that many families and friends have through their experiences sadly become experts in various different areas of mental ill-health, care and treatment," said Mr Griffin."It values that knowledge and intends to liaise with families engaging with the Inquiry and their representatives in relation to the investigation of systemic issues where relevant in each case."He said key themes found in relatives' statements included accounts of inadequate care, poor communication, unsafe environments, and a lack of accountability. Mr Griffin said the inquiry had also been monitoring recent deaths and inquests, including the 2021 death of Elise Sebastian under EPUT inquest jury at Essex Coroner's Court concluded that "poorly administered observations" contributed to the 16-year-old's - which runs the unit - and chief executive Paul Scott apologised to Elise's Griffin said further deaths in mental health settings in 2024 and April 2025 "may point to serious and ongoing issues in Essex". He said coroners had - or were expected to - issue Prevention of Future Deaths Reports, highlighting ongoing systemic issues. Mr Griffin told the hearing in London that the inquiry remained committed to establishing accountability - with staff names including those of junior staff generally could apply for their names to be withheld in line with relevant law and the inquiry's protocol on restriction orders, said Mr Griffin. The independent statutory Lampard Inquiry previous hearings were held in September and November 2024 and May 2025. In response to the government's criticisms of its health plan, Mr Scott said: "As the Inquiry progresses there will be many accounts of people who were much loved and missed over the past 24 years and I want to say how sorry I am for their loss."All of us across healthcare have a responsibility to work together to improve care and treatment for all and to build on the improvements that have already been made over the last 24 years." Follow Essex news on BBC Sounds, Facebook, Instagram and X.
Powys County Times
an hour ago
- Powys County Times
Doctors against Palantir's NHS software put ‘ideology over patient interest'
Doctors who oppose the use of software developed by Palantir in the NHS have 'chosen ideology over patient interest', the UK boss of the tech giant has told MPs. Louis Mosley appeared in front of the Science, Innovation and Technology Committee on Tuesday as part of its innovation showcase. While there, he also challenged claims that Palantir has a 'reputational difficulty' and said it is 'very proud' of the work it does in Israel. Palantir was co-founded by billionaire tech entrepreneur Peter Thiel, who was an early backer of US President Donald Trump, and has worked with the US government. It was announced in November 2023 that a group led by Palantir had secured a £330 million contract to provide the NHS Federated Data Platform (FDP). The shared software system will aim to make it easier for health and care organisations to work together and provide better services to patients, but Palantir's involvement sparked concerns about how patient data will be used. When asked by MPs about how the company protects patient privacy, and if data would be processed outside of the UK, or be accessible by any foreign government, Mr Mosley said: 'The critical thing to bear in mind about the way our software works and the way it's deployed in the NHS, is that the data controllers – so those organisations that have that legal responsibility, in the NHS those are trusts, typically – they maintain control over their data. 'So each of them gets their own instance of our software, and they control who has access to it, they control what data is integrated into it, and they, in effect, implement and enforce the data protection policies that they deem appropriate.' He also emphasised Palantir does not 'derive any economic benefit from the data, the data belongs to the customer'. Mr Mosley claimed that medics who oppose Palantir's involvement in the FDP as choosing 'ideology over patient interest'. It comes after the British Medical Association (BMA) passed a motion stating the company is an 'unacceptable choice' for the FDP at its annual representative meeting in Liverpool last month. The union's members voted in favour of the BMA lobbying against the introduction of Palantir software in the health service, and called for the Department of Health and Social Care to create an audit of the progress of the uptake of the systems throughout the NHS. When asked about this, Mr Mosley said: 'I was very disappointed to see that. I think the accusation that we lack transparency or this is secretive is wrong. 'I think the BMA has, if I may be frank, chosen ideology over patient interest. 'I think our software is going to make patient lives better; so making their treatment quicker, more effective, and ultimately the healthcare system more efficient. 'And I, as a patient, and a user of the NHS, I want it to be as quick and efficient as possible. 'I'm very sad, frankly, that the ideology seems to have taken precedence over those interests.' The BMA vote comes a little over a year since health workers blockaded the entrance to NHS England's headquarters to call for an end to Palantir's contract. In April 2024, hundreds of NHS workers protested in central London, holding placards which read 'No Palantir in the NHS' and 'Palantir aids apartheid'. Mr Mosley also pushed back against claims about Palantir's reputation. It was put to Mr Mosley that Palantir has a 'reputational difficulty' by Conservative MP Kit Malthouse. 'Everybody's slightly suspicious of what you do,' he said. 'And part of that reputational difficulty has been caused by your software being used in war on Gaza and the targeting of Palestinians with particular characteristics. 'What protections would you put in place for UK programmes to make sure they're not complicit in the commission of war crimes?' Mr Mosley said he would 'push back' on the question around reputation, adding: 'I think much of that concern and suspicion that you mentioned is the result of misunderstandings about the nature of our software, the nature of our business model and the kind of work we support. 'I would emphasise the fact that we have never worked and will never work in countries that are adversarial to the west, like China or Russia or Iran. 'We do work in Israel. We're proud of the work that we do there. We have provided the Israelis with support since October 7, but also our work there predates those events. 'I can't go into operational details of the way in which our software is used, but I can assure you that I think the systems to which you would think, like Lavender, for example, are not ones that we are involved in.'
